AngioDynamics Inc. (ANGO) awards 17,966 RSUs and performance rights
Rhea-AI Filing Summary
Nighan Warren JR reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. reported that SVP Quality and Regulatory Warren Nighan Jr. received equity awards on July 15, 2026. He was granted 17,966 restricted stock units, vesting in four equal annual installments from July 15, 2027 through 2030, and 17,966 performance rights tied to three-year relative total shareholder return. Following the RSU grant, he directly holds 84,092 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 17,966 shares
Net Buy
2 txns
Insider
Nighan Warren JR
Role
SVP Quality and Regulatory
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance Right F2 | 17,966 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 17,966 | $0.00 | $0.00 |
Holdings After Transaction:
Performance Right — 17,966 shares (Direct);
Common Stock — 84,092 shares (Direct)
Footnotes (2)
- F1. The acquisition of 17,966 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 17,966 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.
- F2. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.
Key Figures
Restricted stock units granted: 17,966 units
Performance rights granted: 17,966 rights
Common stock holdings after grant: 84,092 shares
+3 more
6 metrics
Restricted stock units granted
17,966 units
RSUs granted to Warren Nighan Jr. on July 15, 2026
Performance rights granted
17,966 rights
Performance rights representing a contingent right to receive common stock
Common stock holdings after grant
84,092 shares
Direct common stock ownership following the RSU acquisition
RSU vesting rate
25% per year
Restricted stock units vest in four equal annual installments from 2027 to 2030
Performance payout range
0%-240% of target
Performance rights payout based on three-year total shareholder return relative to a peer group
Performance period length
three years
Total shareholder return measured over a three-year performance period for performance rights
Key Terms
restricted stock units, performance right, total shareholder return, peer group of companies, +1 more
5 terms
restricted stock units financial
"represents 17,966 restricted stock units, each of which represents a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance right financial
"Each performance right represents a contingent right to receive one share"
peer group of companies financial
"relative to a peer group of companies over a three-year performance period"
contingent right financial
"represents a contingent right to receive one share of Common Stock"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did AngioDynamics (ANGO) grant to Warren Nighan Jr.?
AngioDynamics granted SVP Warren Nighan Jr. 17,966 restricted stock units and 17,966 performance rights on July 15, 2026. Each restricted stock unit and performance right represents a contingent right to receive one share of common stock, subject to vesting or performance conditions.
How do the restricted stock units for AngioDynamics (ANGO) vest for Warren Nighan Jr.?
The 17,966 restricted stock units vest in four equal annual installments. Starting July 15, 2027, 25% of the units vest each year on July 15, 2027, 2028, 2029 and 2030, so full vesting occurs over a four-year period.
How are AngioDynamics (ANGO) performance rights for Warren Nighan Jr. determined and paid out?
Each performance right is a contingent right to one common share, with payout between 0% and 240% of target. The percentage earned is based on total shareholder return relative to a peer group over a three-year performance period, including a possible 20% upward or downward adjustment.
What is Warren Nighan Jr.’s common stock holding in AngioDynamics (ANGO) after these awards?
After the July 15, 2026 RSU grant, Warren Nighan Jr. directly holds 84,092 shares of AngioDynamics common stock. This figure reflects his reported direct ownership of common shares following the acquisition of 17,966 restricted stock units.
Over what period is performance measured for AngioDynamics (ANGO) performance rights?
The performance rights use a three-year performance period. Total shareholder return for AngioDynamics is measured relative to a peer group of companies over that three-year span, and the calculated achievement can be adjusted by up to 20% before determining the final payout.
Can Warren Nighan Jr. lose some or all of his AngioDynamics (ANGO) performance rights?
Yes. Between 0% and 200% of the target performance rights are earned, with a potential 20% adjustment, and any shares that do not vest at the end of the three-year performance period are forfeited, meaning those rights are lost.